Scientific publications
SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
Jun 15, 2022
| Magazine: Diabetes Therapy
Javier Escalada 1 2
Type 2 diabetes mellitus (T2D) represents a significant public health problem, with a dramatically increasing prevalence. T2D is considered a progressive disease that develops macro- and microvascular complications such as cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD), which are closely interconnected and constitute the main causes of morbidity and mortality in these patients.
Over time, finding new pharmacological approaches to protect against these cardiorenal events (the “cardiorenal continuum”) has become the fundamental objective of research aimed at these patients.
CITATION Diabetes Ther. 2022 Jun 15. doi: 10.1007/s13300-022-01281-5
Our authors
